Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,146
- Phase 21,063
- Phase 1820
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis140
- Type 1 Diabetes134
- Atopic Dermatitis130
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections113
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland195
- Alabama176
- Florida145
- Arizona141
- New York122
- Massachusetts119
- Texas118
- Illinois81
- Colorado76
Recruiting studies6,230 total
- NCT07584083RecruitingPhase 2
Anifrolumab for Primary Antiphospholipid Syndrome
This trial tests a new drug called anifrolumab in adults with primary antiphospholipid syndrome (a blood clotting disorder). The drug may help reduce clotting and related complications by working with your immune system.
Athens, GreeceAges 18–70 - NCT07584122Recruiting
Increasing HIV Prevention Access in Rio de Janeiro
This study helps people at higher risk of HIV get access to PrEP, a daily medication that prevents HIV infection. The program focuses on underserved communities in Rio de Janeiro and aims to make PrEP easier to access and use.
Nova Iguaçu, Rio de JaneiroAges 15 years+ - NCT07584889RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Relapsed Blood Cancers
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT07585981Recruiting
Budesonide capsules for IgA kidney disease
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
BeijingAges 18 years+ - NCT07585994Recruiting
Probiotic supplement for long-standing type 1 diabetes
This study tests whether taking a specific probiotic (a beneficial bacteria) for 4 weeks can improve immune function and metabolism in people who have had type 1 diabetes for at least 5 years. Researchers believe this probiotic may help the body's remaining insulin-producing cells work better.
AmsterdamAges 18 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+ - NCT07587840RecruitingPhase 2
CAR-T Cell Therapy After Initial Treatment for Follicular Lymphoma
This study tests a new type of immunotherapy called CAR-T cells (designed cells that fight lymphoma) given after you've received standard chemotherapy for follicular lymphoma. The goal is to help prevent the cancer from coming back or growing, especially if your cancer didn't fully disappear or you have high-risk features.
Beijing, Beijing MunicipalityAges 18–85 - NCT07589439RecruitingPhase 2
Testing LQ036 inhaler for poorly controlled asthma
This trial tests a new inhaled medication called LQ036 to see if it can help people whose asthma is not well controlled with their current inhalers. Participants must have had at least one severe asthma flare-up in the last year and show signs of airway inflammation.
ShanghaiAges 12–75 - NCT07592780Recruiting
Building Tolerance to Peanuts in Children and Teens
This study tests whether a treatment program can help children and teenagers with peanut allergies develop tolerance to peanuts over time. The goal is to reduce the risk of serious allergic reactions if they accidentally eat peanuts.
Hong KongAges 2–17 - NCT07594587Recruiting
Ruxolitinib for Graft-Versus-Host Disease
This study looks at how well a medicine called ruxolitinib works for patients with graft-versus-host disease (GVHD)—a condition where donor cells attack your body after a bone marrow or stem cell transplant. The trial aims to understand if ruxolitinib can help control this side effect.
TokyoAges birth+ - NCT07595653Recruiting
Efgartigimod Treatment Experience in Generalized Myasthenia Gravis
This study follows people with generalized myasthenia gravis (a condition causing muscle weakness) who are already starting a medicine called efgartigimod as part of their regular care. Researchers want to understand how this treatment affects your daily life and overall experience with the disease.
Acquaviva delle FontiAges 18 years+ - NCT07599813RecruitingPhase 2
Testing camoteskimab for moderate-to-severe eczema
This study tests a new medication called camoteskimab for adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to creams alone. The drug works by targeting a protein in the body that causes eczema symptoms like itching and inflammation.
Birmingham, AlabamaAges 18–65 - NCT07602088Recruiting
Real-world Study of Two Cancer Drugs for Chronic Lymphocytic Leukemia
This study follows patients with chronic lymphocytic leukemia (CLL)—a blood cancer—who are starting treatment with two drugs called ibrutinib and venetoclax together for a set period of time. Researchers want to understand how well this treatment works and how it affects patients' daily lives in real-world settings, rather than in a controlled lab environment.
BucharestAges 18 years+ - NCT07602595Recruiting
Understanding pain after childhood rheumatic disease or surgery
This study helps researchers learn how young adults (ages 14–26) who had rheumatic disease or orthopedic surgery as children experience pain over time. By understanding your story, the study may help doctors better support others facing similar challenges.
Cincinnati, OhioAges 14–26 - NCT07604987RecruitingPhase 2
New Treatment for Brain Lymphoma (R-PMDT)
This trial tests a combination drug treatment called R-PMDT for patients newly diagnosed with a type of lymphoma that starts in the brain (PCNSL). The goal is to see if this regimen can help control the cancer and improve outcomes.
TianjinAges 18 years+ - NCT07605806RecruitingPhase 1/Phase 2
Understanding Drug Reactions to Vancomycin
This research study tests a new antibiotic called vancomycin to understand how the body reacts to it and identify early warning signs. If you qualify, you'll help researchers learn more about sudden allergic-like reactions that aren't traditional allergies.
Baltimore, MarylandAges 18 years+ - NCT07605845RecruitingPhase 1
Testing GL-2045 Safety in Immune Thrombocytopenia Patients
This trial tests a new drug called GL-2045 for immune thrombocytopenia (ITP)—a condition where your body destroys its own platelets, causing low platelet counts and bleeding risks. The study checks if GL-2045 is safe and effective for people whose platelet counts haven't been controlled well enough with other treatments.
LeedsAges 18–80 - NCT07606703RecruitingPhase 2
Madecassoside for Hardened Skin After Bone Marrow Transplant
This trial tests whether a plant-derived medicine called madecassoside can help treat sclerotic chronic graft-versus-host disease (a hardening and tightening of the skin that sometimes happens after bone marrow transplant). You would take tablets and be monitored to see if your skin condition improves.
Wuhan, HubeiAges 14–65 - NCT07608978RecruitingPhase 2
New drug combination for untreated aggressive lymphoma
This study tests a combination of five drugs (including a targeted therapy called polatuzumab vedotin) for patients with a specific type of aggressive lymphoma (DLBCL) that has never been treated before. The goal is to see if this combination works better and is safe for certain subtypes of this cancer.
Nanjing, JiangsuAges 18 years+ - NCT07609030Recruiting
Brain Training During CAR-T Cell Cancer Treatment
This study tests whether special brain exercises can help protect thinking and memory skills during CAR-T cell therapy—a newer cancer treatment for certain blood cancers. Researchers want to see if training your brain during treatment reduces side effects on memory and mental function.
Columbus, OhioAges 18 years+ - NCT07609134Recruiting
Testing a self-management program for adults with asthma
This study tests a new asthma self-management program designed to help adults better control their asthma in their regular doctor's office. The program teaches practical skills to manage your asthma day-to-day and may help reduce symptoms and improve quality of life.
Dublin, DAges 18 years+ - NCT07609576Recruiting
Tracking Infections in Blood Cancer Patients on Bispecific Antibody Treatment
This study follows adults with blood cancers (like multiple myeloma or lymphoma) who are starting a newer type of immunotherapy called bispecific antibodies. Researchers want to understand what infections might develop during this treatment and how often they occur, which could help doctors better protect patients.
Madrid, MadridAges 18 years+ - NCT07610447Recruiting
Virtual Reality vs Treadmill Exercise for Kids With Asthma
This study compares two ways to exercise safely: using virtual reality versus a treadmill. Researchers want to see which method helps children and teens with asthma improve their fitness and breathing.
Istanbul, EyupsultanAges 10–17 - NCT07611747RecruitingPhase 4
Ultrasound Screening to Prevent Heart Disease in Rheumatic Patients
This study tests whether using ultrasound to look at arteries in the neck can help prevent heart attacks and strokes in people with inflammatory joint diseases like rheumatoid arthritis or lupus. Researchers will use the results to guide treatment decisions.
Alicante, AlicanteAges 50 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,786 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.